Currently in Orlando Florida the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium is in progress. There are a number of very interesting abstracts that pertain to those of us who have advanced prostate cancer. In the course of the next few days I will be reviewing a number of these that I [...]
Mortality prospects after a prostate cancer recurrences following a radical prostatectomy has always been assumed to be directly related to the early development of metastases. A study from Melbourne Australia indicates that men with low-risk prostate cancer have good mortality prospects even when they experience early biochemical recurrence. The first author of the study, Anthony [...]
Once you have had primary treatment for prostate cancer you must continue to actively monitor your PSA until you die. There is no cure; at least you should never assume that you have been cured because 1/3 of all men who have treatment will have a recurrence. What treatment you have does not matter, statistically [...]
When facing a post prostatectomy biochemical failure (PSA only failure) the best way to treat is still not known. Preliminary data from Johns Hopkins [1] and Duke Universities[2] have recently provided some of the earliest evidence that salvage radiotherapy may prolong overall survival versus delay of intervention until time of symptomatic progression. Despite [...]
A recently published article in Urology Times claims that salvage high-intensity focused ultrasound (HIFU) appears to be an effective treatment option for locally recurrent prostate cancer after primary external beam radiation therapy (EBRT) failure. The study, which this article reported on, used data from analyses of 6-year oncologic outcomes show. When the researchers did a [...]
There was just a new site opened for the early/expanded access program for Alpharedin (Radium-235). The new site is at Stanford University, California. This makes a total of four sites, but most of them have not been adequately supported by the drug company, Bayer. Hopefully, this site will be better supported, but if it too [...]
It is the general consensus that prostate cancer when still confined to the prostate gland is gland curable, but when it has left the prostate gland and becoming metastatic it is no longer curable. But evidence now says there might be an intermediate stage where the cancer has spread outside the prostate gland but is [...]
The FDA has approved c11 choline Injection, a Positron Emission Tomography (PET) imaging agent, for use in men to detect prostate cancer recurrences and to locate specific body sites for follow-up tissue sampling, testing and treatment. The indicated use for c11 choline injection is men with elevated prostate specific antigen (PSA) levels after earlier primary [...]
In a study conducted by Choueiri et al. published in Cancer it was suggested that men who have prostate cancer that was treated by a radical prostatectomy (RP) who then had a long time to a biochemical recurrence (BCR) or a long PSA doubling time after a BCR have no higher overall risk of death [...]
